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Abstract. The dynamics of the indices of fibrinolysis 
and cellular adhesion in patients with chronic diffuse liver 
diseases against the ground of administration of “Triovit”, a 
selenium-containing drug, has been studied. The admini-
stration of “Triovit” in a comprehensive therapy of patients 
with chronic diffuse liver diseases was found to improve 
the indices of the blood plasma fibrinolytic system, to re-
duce adhesive cellular properties and to increase total enzy-
matic activity of the blood plasma.  
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Introduction. Disorders of the endothelial par-
ticipation in the regulation of fibrinolysis are an im-
portant link in pathogenesis of many diseases includ-
ing chronic diffuse liver diseases (CDLD) [1, 2, 4]. 
Disorders of the local fibrinolysis are an important 
factor in the development and progressing of CDLD 
which can be caused  by disorders of the liver circu-
lation, and results in an increased release of throm-
boplastin, a powerful triggering factor of blood clot-
ting, into the blood [5, 6]. 
In its turn, endothelial dysfunction causes oc-
curring and progressing of thyroid homeostasis dis-
orders [3], which is indicative of the necessity to 
elaborate effective methods of its correction.  
Objective: to examine the dynamics of indices 
of the blood fibrinolytic activity and cellular adhe-
sion in patients with chronic diffuse liver diseases 
against the ground of administration of Triovit, a 
selenium-containing drug. 
Materials and methods. 28 CDLD patients 
were examined. 20 practically healthy individuals of 
a corresponding age and sex were included in the 
group for comparison. Patients with chronic hepatitis 
and liver cirrhosis of a viral etiology, Wilson’s dis-
ease, congenital α-antitripsin insufficiency (α-
inhibitor of proteinase), idiopathic (genetic) hemo-
chromatosis, autoimmune hepatitis were not included 
into the study. 
All the patients were divided into two groups 
represented by their age, sex, degree of cytolysis 
activity and liver cirrhosis compensation. The first 
group (a comparative group) included 12 individuals 
afflicted with CDLD receiving a generally accepted 
therapy (diet No 5), hepatoprotectors, diuretics and 
detoxicants in case of need. The main group included 
16 patients with CDLD receiving two Triovit cap-
sules in the morning and in the evening against the 
ground of basic therapy during one month. The diag-
nosis of CDLD was made on the basis of carefully 
collected anamnesis, generally accepted complex of 
clinical-laboratory and instrumental methods of ex-
amination, detection of serum markers of viral hepa-
titis B and C, USD of the abdominal organs and thy-
roid gland.  
The content of soluble intercellular adhesive 
molecule of the 1st type (ICAM-1) was detected by 
means of immune-enzymatic method using the com-
mercial test-system of the “Diaclone” firm (France). 
The total (TFA), non-enzymatic (NFA) and 
enzymatic fibrinolytic activity (EFA) of the citrate 
blood plasma was detected by means of azofibrin 
lysis (Simko Ltd., Ukraine).  
Peculiarities of thyroid homeostasis were stud-
ied by the content of free thyroxin (fT4), free thriio-
dothyronine (T3) and thyrotrophic hormone (TTH) 
by means of immune-enzymatic method using the 
reagents “ImmuneFa-TTH”, “IFA-SvT3” and “IFA-
SvT4-1” (JSC “Immunotech”) on the analyzer of 
immune-enzymatic reactions “Uniplan” calculating 
the coefficients fT3/fT4, fT4/fT3. 
The results obtained were processed by means 
of Biostat program using Student t-criterion. 
Results and discussion. The level of ICAM-1 
in the blood plasma of CDLD patients was 34,6 % 
higher (P<0,001). 
Examination of blood fibrinolytic activity de-
tected a reliable decrease of TFA index on 20,2 % 
(P<0,001) at the expense of reduced enzymatic por-
tion of fibrinolysis (EFA on 45,5 %, P<0,001). The 
index of non-productive NFA, being 35,2 % higher 
(P<0,001) that of the control, increased against this 
ground. 
Thus, CDLD patients demonstrate inhibition of 
fibrinolytic blood plasma activity occurring at the 
expense of inhibition of enzymatic fibrinolysis as 
well as compensatory increase of non-enzymatic 
fibrinolytic activity. 
According to the data of correlation analysis the 
development of fibrinolytic system disorders in pa-
tients with dysmetabolism of thyroid hormones 
against the ground of CDLD is connected with hy-
potriiodthyroninemia and conversion disorders of 
free thyroid hormones. 
Thus, endothelial dysfunction caused by patho-
logical mechanisms such as oxidant stress and in-
creased cellular adhesion is likely to inhibit fibri-
nolytic blood activity in the examined patients. 
The results of Triovit effect upon the indices of 
cellular adhesion and fibrinolytic blood plasma activ-
ity of CDLD patients are presented in the table. 
Examination of the dynamics of ICAM-1 con-
tent in the blood serum detected more considerable 
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Fig. 1 Dynamics of the content of the 1st type intercellular adhesion molecules (ICAM-1) in the blood serum of patients with 

























Fig. 2. Dynamics of the total fibrinolytic activity of the blood plasma in patients with chronic diffuse liver diseases in the 
course of treatment 
decrease of the cellular adhesive properties in the 
main group. This index was 10,3 % lower (P<0,001) 
in a month against the basic therapy, and 17,8 % 
lower (P<0,01) against Triovit administration (fig. 1).  
In 14 days the patients of the main group dem-
onstrated a reliable increase of TFA index on 13,7 % 
(P<0,01), in a month – on 20,6 % (P<0,001), at the 
same time in the comparative group these changes 
were reliable only in a month after the treatment 
(P<0,01) (fig. 2).  
After Triovit use NFA reduction on 10,0 % 
(P<0,05) and 15,9 % (P<0,01) was registered 2 
 115 
Буковинський медичний вісник        Том 18, № 2 (70), 2014 
 
Рецензент – проф. О.І. Волошин                                     Buk. Med. Herald. – 2014. – Vol. 18, № 2 (70). – P. 113-115 
Надійшла до редакції 29.01.2014 року 
 
© K.A. Chympoy, N.V. Pashkovska, O.I. Fediv, N.M. Pavlibroda, 2014 
weeks and 1 month after the treatment, in the pa-
tients treated by means of basic therapy only – on 8,1 
% and 12,5 % (P<0,01). 
The result of the therapy conducted was a reli-
able increase of EFA in the main group 2 weeks after 
the initiation of therapy on 42,6 % (P<0,001) and on 
60,7 % (P<0,001) in a month, in the comparative 
group – on 36,8 % (P<0,01) and 54,4 % (P<0,001) 
respectively. 
Thereby, administration of Triovit, a selenium-
containign drug, in a comprehensive treatment of 
CDLD patients promotes decrease of cellular adhe-
sive properties which is proved by reduced ICAM-1 
expression. TFA increases against this ground at the 
expense of EFA increase.  
Conclusions  
1. Chronic diffuse liver diseases are accompa-
nied by disorders of the blood plasma fibrinolytic 
system, functional endothelial state with inhibition of 
enzymatic fibrinolysis against the ground of in-
creased expression of the 1st type intercellular adhe-
sion molecule.   
2. Addition of Triovit into the therapeutic com-
plex of patients with chronic diffuse liver diseases 
results in the reduction of adhesive cellular proper-
ties (expression of the 1st type intercellular adhesion 
molecule) and the signs of disorders of the blood 
plasma fibrinolytic system (increase of enzymatic 
fibrinolytic activity). 
The prospects of proceeding investigations 
will be further studies of pathogenetic peculiarities 
of thyroid homeostasis disorders under conditions of 
chronic diffuse liver diseases with the aim to find the 
mechanisms of their occurrence and progress and 
substantiation of the improved methods to correct 
and prevent the given pathology.  
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ПАТОГЕНЕТИЧЕСКОЕ ОБОСНОВАНИЕ КОРРЕКЦИИ НАРУШЕНИЙ СИСТЕМЫ  
ФИБРИНОЛИЗА ПЛАЗМЫ КРОВИ У БОЛЬНЫХ ХРОНИЧЕСКИМИ ДИФФУЗНЫМИ  
ЗАБОЛЕВАНИЯМИ ПЕЧЕНИ С НАРУШЕНИЕМ ТИРЕОИДНОГО ГОМЕОСТАЗА 
К.А. Чимпой, Н.В. Пашковская, О.И. Федив, Н.М. Палиброда 
Резюме. Изучена динамика показателей фибринолиза и клеточной адгезии у больных хроническими диффуз-
ными заболеваниями печени на фоне использования селенсодержащего препарата «Триовит». Установлено, что 
триовит в комплексной терапии больных хроническими диффузными заболеваниями печени способствует оптими-
зации показателей фибринолиза плазмы крови, позволяет существенно уменьшить адгезивные свойства клеток и 
повысить суммарную ферментативную активность плазмы крови.  
Ключевые слова: хронические диффузные заболевания печени, тиреоидный гомеостаз, клеточная адгезия, 
фибринолиз, триовит. 
ПАТОГЕНЕТИЧНЕ ОБҐРУНТУВАННЯ КОРЕКЦІЇ ПОРУШЕНЬ СИСТЕМИ ФІБРИНОЛІЗУ 
ПЛАЗМИ КРОВІ У ХВОРИХ НА ХРОНІЧНІ ДИФУЗНІ ЗАХВОРЮВАННЯ ПЕЧІНКИ  
З ПОРУШЕННЯМ ТИРЕОЇДНОГО ГОМЕОСТАЗУ 
К.А. Чимпой, Н.В. Пашковська, О.І. Федів, Н.М. Паліброда 
Резюме. Вивчено динаміку показників фібринолізу та клітинної адгезії у хворих на хронічні дифузні захворю-
вання печінки на тлі використання селеновмісного препарату «Триовіт». Встановлено, що триовіт у комплексній 
терапії хворих на хронічні дифузні захворювання печінки сприяє оптимізації показників системи фібринолізу плаз-
ми крові, дозволяє істотно зменшити адгезивні властивості клітин та підвищити сумарну ферментативну активність 
плазми крові.  
Ключові слова: хронічні дифузні захворювання печінки, тиреоїдний гомеостаз, клітинна адгезія, фібриноліз, 
триовіт.  
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